Prostate Specific Antigen, Ultrasensitive
Use to monitor prostate cancer after radical prostatectomy. Do not use for initial prostate cancer screening; preferred test is Prostate Specific Antigen, Total (0070121) in conjunction with digital rectal exam.
Quantitative Electrochemiluminescent Immunoassay
Within 24 hours
New York DOH Approval Status
Serum Separator Tube (SST). Also acceptable: Green (lithium heparin), Lavender (K2EDTA, or Pink (K2EDTA).
Allow specimen to clot completely at room temperature. Separate from cells ASAP or within 2 hours of collection. Transfer 1 mL serum or plasma to an ARUP Standard Transport Tube. (Min: 0.5 mL)
Grossly hemolyzed specimens. Vaginal washings.
After separation from cells: Ambient: 24 hours; Refrigerated: 5 days; Frozen: 6 months
After radical prostatectomy, the reference interval is less than 0.05 ng/mL if there is no residual disease. In healthy individuals without prostatectomy, the reference interval is 4.00 ng/mL or less. Lower limit of detection is 0.01 ng/mL.
The Roche PSA electrochemiluminescent immunoassay is used. Results obtained with different test methods or kits cannot be used interchangeably. The Roche PSA method is approved for use as an aid in the detection of prostate cancer when used in conjunction with a digital rectal exam in individuals with a prostate 50 years and older. The Roche PSA is also indicated for the serial measurement of PSA to aid in the prognosis and management of prostate cancer patients. Elevated PSA concentrations can only suggest the presence of prostate cancer until biopsy is performed. PSA concentrations can also be elevated in benign prostatic hyperplasia or inflammatory conditions of the prostate. PSA is generally not elevated in healthy individuals or individuals with nonprostatic carcinoma.
|Component Test Code*||Component Chart Name||LOINC|
- Post Prostatectomy
- PSA, Third Generation
- Ultrasensitve PSA